New cell-based assay shown to rapidly profile drug resistance to three widely used SARS-CoV-2 main protease inhibiting drugs

In a recent study posted to the bioRxiv* pre-print server, researchers tested three next-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) inhibitors, namely, nirmatrelvir, ensitrelvir, and FB2001, using a novel cell-based assay.